Optimapharm acquires Swiss Denothex

Published on: 

Applied Clinical Trials

Optimapharm, an independent clinical research organization (CRO), acquired Denothex Ltd. Optimapharm operates in offices across 14 European countries. It covers markets with a total population of over 500 million people, and conducts phase I – IV clinical research across Europe with a very strong footprint in Central and Eastern Europe.

Read the full release here.